Product Information
AFREZZA (REGULAR INSULIN) 60-4 UNIT/60-8 UNIT/60-12 UNIT is a brand product labeled by Mannkind Corporation, priced at $10.3329 per EA under NDC 47918090218. Its NADAC has been published 190 times since Aug 21, 2019.
Manufacturer
Mannkind CorporationNDC
47918090218
Classification
Brand
Dosage Form
KIT
Route
RESPIRATORY (INHALATION)
Effective Date
9/23/2026
Approval Type
Biologic (BLA)
FDA Application
BLA022472On Market Since
1/10/2017
Price Statistics
The NADAC for AFREZZA (REGULAR INSULIN) 60-4 UNIT/60-8 UNIT/60-12 UNIT has been published 190 times since Aug 21, 2019, and over the history we have for it it has risen 49.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $10.3329 per EA |
|---|---|
| All-time high | $10.3685 (Aug 12, 2026) |
| All-time low | $6.9261 (Aug 21, 2019) |
| 52-week high | $10.3685 |
| 52-week low | $10.0714 |
| Median price | $9.6663 |
| Average price | $9.2131 |
| Largest weekly change | +27.6% (Apr 17, 2024) |
| Weeks tracked | 190 |
| Tracking since | Aug 21, 2019 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 25% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Mannkind Corporation manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
INSULIN HUMAN market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of AFREZZA (REGULAR INSULIN) 60-4 UNIT/60-8 UNIT/60-12 UNIT?
The current National Average Drug Acquisition Cost (NADAC) for AFREZZA (REGULAR INSULIN) 60-4 UNIT/60-8 UNIT/60-12 UNIT, manufactured by Mannkind Corporation, is $10.3329 per EA (NDC 47918090218), effective Sep 30, 2026.
How has the price of AFREZZA (REGULAR INSULIN) 60-4 UNIT/60-8 UNIT/60-12 UNIT changed over time?
Over the history we have for it, the NADAC for AFREZZA (REGULAR INSULIN) 60-4 UNIT/60-8 UNIT/60-12 UNIT has risen 49.2%. It has been tracked across 190 weekly CMS publications since Aug 21, 2019.
What are the highest and lowest recorded NADAC prices for AFREZZA (REGULAR INSULIN) 60-4 UNIT/60-8 UNIT/60-12 UNIT?
Since Aug 21, 2019, the NADAC for AFREZZA (REGULAR INSULIN) 60-4 UNIT/60-8 UNIT/60-12 UNIT has ranged from a low of $6.9261 (Aug 21, 2019) to a high of $10.3685 (Aug 12, 2026), with a median of $9.6663 per EA.
Are there cheaper alternatives to AFREZZA (REGULAR INSULIN) 60-4 UNIT/60-8 UNIT/60-12 UNIT?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, AFREZZA (REGULAR INSULIN) 90-4 UNIT / 90-8 UNIT, is $7.7805 per EA — about 25% below AFREZZA (REGULAR INSULIN) 60-4 UNIT/60-8 UNIT/60-12 UNIT.
Who manufactures AFREZZA (REGULAR INSULIN) 60-4 UNIT/60-8 UNIT/60-12 UNIT?
AFREZZA (REGULAR INSULIN) 60-4 UNIT/60-8 UNIT/60-12 UNIT (NDC 47918090218) is labeled by Mannkind Corporation, and CMS classifies it as a brand product.